ArticleBMJ open2021

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.

Paul J Cacciottolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.